Newsfeeds - Spark Newswire

1 minute read

Core & Main Announces Upsize And Pricing Of Secondary Offering By Selling Shareholders; Offering Now 11M shares At $23.75/Share

September 16, 8:01 AM

Core & Main, Inc. (NYSE:CNM), a leading specialized distributor of water, wastewater, storm drainage and fire protection products, and related services, announced the upsize and pricing of the previously announced

CNM

1 minute read

Core & Main Files For Offering Of Shares Of Common Stock By Selling Stockholders, Size Not Disclosed

By Michael Horton

September 15, 4:23 PM

-Reuters

CNM

1 minute read

RBC Capital Maintains Outperform on Core & Main, Raises Price Target to $27

By Benzinga Newsdesk

September 15, 7:33 AM

RBC Capital analyst Mike Dahl maintains Core & Main (NYSE:CNM) with a Outperform and raises the price target from $25 to $27.

CNM

1 minute read

Analyst Ratings

Credit Suisse Maintains Outperform Rating for Core & Main: Here’s What You Need To Know

By Benzinga Insights

September 14, 12:15 PM

Credit Suisse has decided to maintain its Outperform rating of Core & Main (NYSE:CNM) and raise its price target from $29.00 to $32.00. Shares of Core & Main are trading up 0.18% over the last 24 hours, at $25.16 per share.

CNM

1 minute read

Truist Securities Maintains Hold on Core & Main, Raises Price Target to $28

By Benzinga Newsdesk

September 14, 10:00 AM

Truist Securities analyst Keith Hughes maintains Core & Main (NYSE:CNM) with a Hold and raises the price target from $25 to $28.

CNM

1 minute read

Credit Suisse Maintains Outperform on Core & Main, Raises Price Target to $32

By Benzinga Newsdesk

September 14, 7:21 AM

Credit Suisse analyst Jamie Cook maintains Core & Main (NYSE:CNM) with a Outperform and raises the price target from $29 to $32.

CNM

1 minute read

Goldman Sachs Maintains Neutral on Core & Main, Raises Price Target to $29

By Benzinga Newsdesk

September 14, 7:07 AM

Goldman Sachs analyst Joe Ritchie maintains Core & Main (NYSE:CNM) with a Neutral and raises the price target from $26 to $29.

CNM

6 minute read

Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday

By Lisa Levin

September 14, 3:58 AM

Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX dose groups.

AAPL